Physician profile
Gregory D Borak
NPI 1255333142
$5,189.04
in general payments reported to CMS, 2019-2025
32 companies · $958 in 2025
The $958 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $825 · 2021: $268 · 2022: $928 · 2023: $1,043 · 2024: $627 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,627.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,909.68 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Fujifilm Healthcare Americas Corporation | $658.83 | 2020 | |
| Boston Scientific Corporation | $457.18 | 2022-2023 | Exalt Model D, Cre Pro |
| Celgene Corporation | $268.27 | 2021-2024 | Zeposia |
| Medtronic, INC. | $262.63 | 2023-2025 | Interstim, Gi Genius |
| Pfizer INC. | $231.79 | 2019-2025 | |
| Gilead Sciences, INC. | $231.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.13 | 2019-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $126.27 | 2019-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $95.27 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $86.35 | 2022-2025 | Sucraid |
| Janssen Biotech, INC. | $75.12 | 2021-2025 | Stelara, Simponi Aria, Remicade |
| Ardelyx, INC. | $54.66 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $54.21 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $50.72 | 2022-2024 | Dificid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $49.74 | 2020 | |
| Ucb, INC. | $47.46 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $44.31 | 2024-2025 | Iqirvo |
| Organon LLC | $35.09 | 2023 | Renflexis, Hadlima |
| Lilly USA, LLC | $34.61 | 2023-2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $24.59 | 2021-2022 | |
| Redhill Biopharma INC. | $21.56 | 2020 | |
| Mirum Pharmaceuticals, INC. | $20.84 | 2025 | Livmarli |
| Olympus America INC. | $20.72 | 2019 | |
| Daiichi Sankyo INC. | $18.48 | 2019 | |
| Shire North American Group INC | $17.82 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.38 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.84 | 2023 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $16.58 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $14.56 | 2021 | |
| Romark Laboratories, Lc | $8.91 | 2019 | |
| Travere Therapeutics, INC. | $7.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Borak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.